Glaxo gains EU conditional clearance for Novartis vaccines deal
MLex Summary: The European Commission has approved GlaxoSmithKline’s plan to buy Novartis’s vaccine business and to take sole control of a new consumer-healthcare joint venture with the Swiss company, subject to conditions....To view the full article, register now.
Already a subscriber? Click here to view full article